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Abstract
AIM: To investigate the metabolic enzymatic capacity 
of the colon mucosa to detoxify noxious carcinogenic 
compounds. 
METHODS: We investigated the activity of 2 conju-
gating enzymes-the microsomal uridine glucurono-
syltransferase (UGT) and the cytosomal glutathione 
S-transferase (GST) in the uninvolved mucosa of the 
colon transversum and sigmoideum in patients with ad-
enomatous polyps and colorectal cancer. Biopsies were 
taken from the mucosa during colonoscopies which 
were done for clinical (diagnostic) reasons. After stor-
age, the biopsy material was homogenized and after 
differential centrifugation the enzyme assays were per-
formed with 4-nitrophenol (UGT) and 1-chloro 2,4-dini-
trobenzene (GST) as substrates.
RESULTS: About 48 patients were included of which 
28 had adenomas and 20 had colorectal carcinomas 
confirmed by histopathology. Enzyme activities were 
expressed as nmol/mg per minute protein for the GST 
and as pmol/mg per minute protein for the UGT. Analy-
sis of variance (F -test) indicated that both enzymes 
were more widely distributed in adenoma than in can-
cer patients. The means ± SD were smaller for cancer 
patients: GST for adenomas 268 ± 152 vs  241 ± 69 for 
carcinomas and UGT for adenomas 197 ± 200 vs  150 
± 86 for carcinomas. 
CONCLUSION: Compared to patients with adenoma-
tous colon polyps those with colorectal carcinoma ex-
hibited a lower capacity of detoxifying enzyme metabo-
lism and their activities clustered over a smaller range. 
© 2013 Baishideng. All rights reserved.
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Core tip: Protective enzymes can conjugate carcinogen-
ic chemicals. The functional capacity of these enzymes 
is diminished in patients with colorectal cancer and in 
some patients with colon adenomas.
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INTRODUCTION
Colorectal cancer is an important cause of  cancer death 
in Western countries. In Europe, colorectal cancer (CRC) 
is the second cause of  death from malignant disease 
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after lung cancer[1]. It is estimated that up to 10% of  
CRC cases can be attributed to hereditary factors leav-
ing approximately 90% of  so called sporadic colorectal 
cancer cases, which may be attributed to diet and lifestyle 
factors[2]. Epidemiological studies have shown the im-
portance of  dietary habits in the risk for CRC. Diets low 
in fruit and vegetables, and high in red meat and fat are 
associated with an increased risk of  CRC[3,4]. Humans 
may be daily exposed to a large variety of  toxic or even 
carcinogenic compounds, present in food[5] or as a result 
of  lifestyle habits such as smoking or use of  alcohol[6,7]. 
However, humans possess a highly efficient system of  
defense against such harmful compounds. Detoxification 
enzymes such as UDP-glucuronosyltransferases (UGTs)[8] 
and glutathione S-transferases (GSTs)[9] are responsible 
for the efficient modification and detoxification of  harm-
ful molecules. These enzymes are present in many tissues 
and also in the gastrointestinal tract in esophagus, stom-
ach, small intestine, large intestine and in the liver[8-11]. 
UDP-glucuronosyltransferases catalyze the conjugation 
with glucuronic acid of  a wide variety of  exogenous 
compounds (e.g., drugs, pesticides, tobacco smoke com-
ponents such as benzo(a)pyrene) as well as endogenous 
compounds (e.g., bilirubin, bile acids, steroid hormo-
nes)[8]. Glutathione S-transferases catalyze the reaction 
of  glutathione with mainly exogenous electrophiles (e.g., 
polycyclic aromatic hydrocarbons, heterocyclic amines) 
and endogenous products of  oxidative stress[9]. The 
conjugates formed by these enzyme reactions are gener-
ally less toxic than their precursors and are more water-
soluble, which facilitates their biliary and renal excretion. 
The gastrointestinal tract is in direct contact with poten-
tially toxic or (pre) carcinogenic agents, ingested by food, 
medication, drugs, etc. and the intestinal mucosa acts as a 
first-line barrier[12]. Tissue-specific expression of  the dif-
ferent isoforms of  GSTs and UGTs in colon and liver 
was demonstrated to result in the differences in enzyme 
activities as measured in these tissues[10,11,13,14]. 
Earlier, we demonstrated an inverse relationship be-
tween GST enzyme activity and cancer risk in several 
organs of  the gastrointestinal tract[15], suggesting that the 
levels of  phase Ⅱ detoxification enzymes could be pivot-
al in cancer prevention. After comparison of  detoxifica-
tion levels in small intestine (a site of  low cancer risk) and 
large intestine (high cancer risk), we even postulated that 
the levels of  detoxification enzymes in the colon could 
be critically low[16]. 
We now investigated mucosal GST and UGT de-
toxification activities in normal mucosa of  patients 
with colorectal adenomas, which are at risk to develop 
colorectal cancer, and in patients who already did develop 
colorectal cancer. Individual susceptibility to CRC could 
be partly due to low levels of  detoxification enzymes. 
MATERIALS AND METHODS
Patients
Fifty-one patients gave their written informed consent to 
use additional biopsy material for this study, the protocol 
of  which was approved by the Ethics Committee of  the 
university of  Dresden/Germany. Colonoscopies were 
performed exclusively for clinical (diagnostic) reasons in 
all patients and colorectal cancer or adenomas were con-
firmed in n = 48 patients. Figure 1 shows the characteris-
tics of  the 48 patients included in the statistical analyses 
of  the study. Endoscopic findings were confirmed by 
histopathology using a standard protocol. Information 
on the clinical variables was taken from the patients’ clini-
cal files. Consecutive patients with adenomatous polyps 
or colorectal cancers were included regardless of  localiza-
tion, size, stage and histological grading. All patients with 
neoplasia of  the colon were included if  there was patho-
logically proven neoplasia. We excluded patients with in-
sufficient clinical data and those without biopsies of  the 
uninvolved mucosa. 
Methods
Forceps biopsies of  the colon mucosa were taken from 
the uninvolved mucosa of  the transversum and the sig-
moid colon. Biopsy material was shock-frozen and stored 
in liquid nitrogen until analysis. Biopsies were weighed 
and homogenized by 15 strokes in a plastic/plastic potter 
in 5 volumes of  a buffer solution (pH = 7.4) contain-
ing 0.25 mol/L saccharose, 20 mmol/L Tris/HCl and 1 
mmol/L dithiothreitol (all chemicals were from Sigma, 
Zwijndrecht, The Netherlands). Half  of  the total ho-
mogenate was frozen at -80 ℃ in small aliquots and used 
for the UGT assay. The other half  of  the homogenate 
was used for preparation of  cytosol by centrifugation for 
60 min at 150000 g and at 4 ℃ in a 42.2Ti rotor (Beckman 
Optima L-70K). The supernatant (cytosol) was frozen 
at -80 ℃ in small aliquots and used for the GST assay. 
Protein content was determined in cytosol (2 × 5 µL) 
and homogenate (2 × 5 µL) and GST enzyme activity in 
the cytosolic fractions (2 × 10 µL) was determined with 
1-chloro-2,4-dinitrobenzene as substrate as described 
before[17]. UGT enzyme activity in the homogenates (1× 
20 µL) was measured with 4-nitrophenol as substrate ac-
cording to Strassburg et al[18] Usually, 2-3 biopsy particles 
per patient were taken from each site (uninvolved colon 
transversum and colon sigmoideum). For some patients 
not enough biopsy material was obtained to perform the 
complete set of  enzyme assays (Figure 1). Combined 
activity was calculated as the mean of  the activity of  
sigmoid and transversum when both locations were bi-
opsied per patient, otherwise as the activity of  one of  the 
two locations only. 
Statistical analysis
Patient characteristics were analyzed using descriptive sta-
tistical methods. Enzyme activities in the different groups 
analyzed were described using means and standard devia-
tions and compared using the t-test. An F-test was used 
to compare the variances in the two groups. The correla-
tion between GST and UGT was described numerically 
using the Spearman correlation coefficient and graphi-
cally using linear regression exhibiting both confidence 
intervals (for the means) and prediction intervals for the 
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actual values. SAS/STAT software, Version 9.3 was used 
for all statistical analyses. P-values ≥ 0.05 were identified 
as not significant (NS) throughout this paper. 
RESULTS
We investigated whether patients with adenomas or CRC 
differed in their colon capacity to metabolize noxious 
chemical compounds using the activities of  detoxify-
ing conjugating phase Ⅱ enzymes as biomarkers. Table 
1 shows the patients’ demographic characteristics: 20 
patients had colorectal carcinomas with stage 2 and 3 
and 28 patients had adenomatous polyps of  various 
location, size and histological types. In 3 patients the 
diagnosis remained unclear as to the type of  neoplasia. 
The means for GST enzyme activity were lower in the 
cancer patients than in adenoma patients (except for the 
transversum), but this difference did not reach statistical 
significance (Table 2). The UGT means were also lower 
in cancer patients even when distinguishing between the 
transversal and sigmoidal location. While the means of  
enzyme activities were not significantly different when 
using a t-test it was obvious that the ranges and the 
standard deviations were much wider for the adenoma 
patients. Adenoma patients had a wider distribution and 
cancer patients aggregated at a lower level and over a 
smaller range. This difference, indicated by the size of  
the standard deviations could be manifested by using 
the F-test which showed a statistically significant differ-
ence for UGT both in the transversum and sigmoid and 
for GST in the sigmoid. Figure 2 shows the individual 
distribution of  the UGT and GST enzyme activity in the 
colon transversum of  adenoma patients (left panel) and 
CRC patients (right panel) in the form of  a regression 
analysis with the 95%CIs (for the means) and prediction 
intervals (for the actual values). The range was narrower 
for the cancer patients. No statistically significant differ-
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48 patients included: 33 
males, 15 females
28 adenoma patients 20 carcinoma patients
27 sigma 
biopsies
19 transversum 
biopsies
19 sigma 
biopsies
18 Transversum 
biopsies
27 GST  23 UGT  19 GST  17 UGT  19 GST  17 UGT  18 GST  16 UGT
Figure 1  Flow-cart: Glutathione S-transferase- and uridine glucuronosyltransferase activities examined from biopsies of adenoma and carcinoma pa-
tients. The number of patients in each type of neoplasia, the number of biopsy sites and the number and type of enzyme assays performed per site are shown. GST: 
Glutathione S-transferase; UGT: Uridine glucuronosyltransferase. 
Table 1  Patient characteristics  n  (%)
Characteristics Colorectal cancer 
(n  = 20)
Adenomas 
(n  = 28)
P -value
Sex 0.0011
   Male   9 (45) 24 (86)
   Female 11 (55)   4 (14)
Age, yr, mean 
(min-max)
68.4 68.4 NS2
(39-86) (51-88)
Alcohol 0.0211
   Yes   3 (16) 15 (54)
   No 17 (84) 13 (46)
Smoking NS1
   Yes   3 (16)   2 (16)
   No 17 (84) 26 (84)
Aspirin NS1
   Yes   2 (10)   5 (18)
   No 18 (90) 23 (82)
NSAIDs 0 (0) 1 (3) NS1
   Yes   20 (100) 27 (97)
   No
BMI (kg/m2) 25.1 25.6 NS2
Distribution of clinical factors among patients with carcinomas and 
adenomas of the colon. 1χ2 test; 2Wilcoxon Rank Sum test. NSAID: 
Nonsteroidal ani-inflammatory drugs; BMI: Body mass index; NS: Not 
significant. 
Table 2  Enzyme activities of glutathione S-transferase and 
uridine glucuronosyltransferase in the normal colon mucosa 
of patients with adenoma and carcinoma (mean ± SD)
Enzyme activities Adenomas 
(n  = 28)
Carcinomas 
(n  = 20)
 P -value 
(F -test)
GST (nmol/mg per minute)
   Transversum 225 ± 104 (19) 237 ± 72 (18) 0.1342
   Sigmoid 265 ± 152 (27) 232 ± 78 (19) 0.0046
   Combined  268 ± 152 (28) 241 ± 69 (20) 0.0007
UGT (pmol mg per minute)
   Transversum 231 ± 269 (17)   159 ± 122 (16) 0.0015
   Sigmoid 170 ± 158 (23) 144 ± 96 (17) 0.0456
   Combined 197 ± 200 (27) 150 ± 86 (19) 0.0005
Number of enzyme assays given in brackets. GST: Glutathione 
S-transferase; UGT: Uridine glucuronosyltransferase. 
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the uninvolved normal appearing mucosa of  patients 
with benign and malign neoplasia of  the colon. Usually 
enzyme values can be expressed using mRNA and pro-
tein levels, but these parameters do not reflect the func-
tional activity within the epithelial cells of  the mucosa. 
Using kinetic data we could obtain direct information on 
the metabolic capacity of  the tissue. Both UGT and GST 
had a significantly different distribution between patients 
with benign neoplasia (adenomas) and those with cancer-
ous neoplasia (CRC). The type of  neoplasia was associ-
ated with the enzyme levels and an increased variance 
was found in the polyp patients. On the other hand the 
enzyme levels could inform on the degree of  neoplasia 
and its evolution. Cancer patients had a smaller range at a 
lower level. This could mean that cancer patients had lost 
some of  the mucosal detoxifying potential, predispos-
ing them to develop cancer. The wide range of  enzyme 
values could indicate that some patients with adenomas 
who were in the lower range might be at risk to develop 
cancer. It is possible that adenoma patients who are in 
the higher range are protected from cancer development 
since they possess a higher protective enzyme capacity. 
This hypothesis needs to be validated by longitudinal 
follow-up studies of  enzyme values in polyp patients over 
long periods of  time. Previously, we found in the rectum 
of  healthy controls GST-levels of  321 ± 29 nmol/mg per 
minute protein (n = 10)[19] which were higher than those 
reported in this paper. 
The UGT enzyme system is located in the endoplas-
mic reticulum of  the mucosal intestinal cells and these 
enzymes can detoxify hazardous chemical compounds - 
mostly lipophilic - which penetrate deep into the interior 
of  the cells. The GST enzymes are located within the 
cytoplasm of  the cells and use intracellular glutathione 
to protect the cells from electrophilic chemicals. Both 
enzymes perform conjugation reactions and thereby 
render xenobiotics water-soluble (phase Ⅱ metabolism). 
The conjugated metabolites can be readily excreted by 
ences of  enzyme levels were found between the transver-
sum and sigma, both, for UGT and GST. For this reason 
the means from the transversum and the sigma were also 
pooled for the analysis of  the combined enzyme levels.
The enzyme activities could be influenced by a variety 
of  clinical factors. Using the clinical charts we examined 
the major clinical variables to find out if  these were af-
fecting the enzyme levels. Both enzymes activities were 
not influenced by age, alcohol and nicotin consumption, 
use of  aspirin or other nonsteroidal anti-inflammatory 
drugs (NSAIDs) and body mass index (BMI). Female 
patients had lower enzyme levels and less variability than 
males (Table 3). There were more males than females 
among the polyp patients (24 vs 4) than among the cancer 
patients (9 vs 11). Also, alcohol consumption was more 
prevalent in the polyp patients (15 vs 13) than in the 
cancer patients (3 vs 17). No differences were detected 
between both groups for nicotin use, aspirin or other 
NSAID medications and body weight.
DISCUSSION
We measured the kinetic detoxifying enzyme activity in 
100
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20
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G
T
Colon transversum n  = 39
Adenomas Carcinomas
100        200        300       400          100        200        300        400
                                              GST
95% prediction limits
95% confidence limits
Regression
Figure 2  Distribution of enzyme values of uridine glucuronosyltransferase and glutathione S-transferase in the colon mucosa of the transversum of 
adenoma and carcinoma patients. The correlation between uridine glucuronosyltransferase (UGT) and glutathione S-transferase (GST) over the range of enzyme 
activities is illustrated in the colon transversum of 39 patients. 
Table 3  Gender differences between glutathione s-transferase 
and uridine glucuronosyltransferase activities in the colon of 
patients with colon-neoplasia
Male Female t -test  F -test
GST (combined)   258 ± 139 (36)  235 ± 68 ( 15) 0.54 0.006
   Transversum 218 ± 94 (26) 251 ± 71 (13) 0.28 0.310
   Sigmoid   267 ± 137 (34) 202 ± 75 (14) 0.10 0.020
UGT (combined)  198 ± 180 (34) 146 ± 99 (15) 0.30 0.020
   Transversum  231 ± 238 (23)   153 ± 108 (12) 0.29 0.009
   Sigmoid  168 ± 142 (29)   141 ± 110 (13) 0.54 0.360
Number of enzyme assays in brackets. For the t-test and the F-test P-values 
are indicated. GST: Glutathione S-transferase; UGT: Uridine glucuronosylt
ransferase. 
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the liver or the kidney. Phase Ⅱ enzymes can be induced 
by their substrates and are influenced by environmental 
chemicals and clinical factors in the human body[20]. In 
contrast to our previous publication[21] there were no sig-
nificant differences of  enzyme levels relating to the loca-
tion between the upper and the lower segments. Howev-
er, this might be due to the different patient population 
(mainly normal and inflammatory findings) investigated 
previously. Female gender was associated with a higher 
prevalence of  carcinomas and lower enzyme activities. 
This might have contributed to the observed enzyme 
disparities. One limitation of  this study was the small 
number of  patients in the 2 groups. Furthermore due to 
the small sample size enzyme values at the m-RNA level 
could not be studied. Further studies should include 
enzyme measurements at the protein and mRNA level. 
More patients and addition of  a control group with non-
neoplastic diseases of  the colon should be included.
Our results suggest that protective enzymes could 
be diminished in the colon mucosa of  cancer patients. 
Reduced activities of  protective enzymes could lead to 
increased susceptibility to develop colorectal cancer. 
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